This trial is designed to find a safe dose of CX-5461, a new treatment for solid tumors, and to see if it has any effect on the tumors. The trial will also look at whether certain mutations make the tumor more likely to respond to the treatment.
- Advanced Solid Tumors
1 Primary · 3 Secondary · Reporting Duration: Safety cohort review will be conducted every 4 weeks from the date of first patient's enrollment to review safety data, until all patients have been enrolled and evaluated for toxicity, assessed up to 24 months
4 Treatment Groups
Main Study Cohort patients receiving CX-5461 at 325mg/m2
1 of 4
Main Study Cohort patients receiving CX-5461 at 250mg/m2
1 of 4
Exploratory cohort patients receiving CX-5461 at 250mg/m2
1 of 4
Exploratory cohort patients receiving CX-5461 at 325mg/m2
1 of 4
52 Total Participants · 4 Treatment Groups
Primary Treatment: CX-5461 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
In what geographic areas is this clinical experiment taking place?
"This study is being conducted in 7 different locations, two of which are Toronto, New York and Pittsburgh. To reduce the effort required to participate, it would be wise for individuals interested in enrolling to select a clinic nearest them." - Anonymous Online Contributor
What is the highest number of participants included in this research endeavor?
"In order to commence the trial, 52 qualified participants are needed. The Princess Margaret Cancer Centre in Toronto and Memorial Sloan-Kettering Cancer Center in New York City have both opened their doors for volunteers." - Anonymous Online Contributor
Has the FDA granted permission to use CX-5461 in medical treatments?
"Our assessment of CX-5461's safety is a 1 because this is an early stage trial and there are only scant data that suggest its efficacy or lack thereof." - Anonymous Online Contributor
Is enrollment still available for this experiment?
"Clinicaltrials.gov lists this experiment as actively recruiting, with the initial posting taking place on September 8th 2021 and the most recent update occurring on November 11th 2022." - Anonymous Online Contributor